Progressed from previous stage since Feb. 15, 2006
Licensed, alliance, or acquisition
Multiple licenses, including CSL, Ltd.
Proof-of-Concept Molecule
Phase 1
Alzheimer’s Disease, MK-0952
Atherosclerosis, MK-6213
Cancer, MK-0429
Cancer, MK-0646
Cancer, MK-0731
Cancer, MK-0752
Cancer, MK-4721
Cancer, V930
Cardiovascular, MK-0448
Cardiovascular, MK-8141
Diabetes, MK-0893
Diabetes, MK-0941
Diabetes, MK-1642
Diabetes, MK-3887
Endocrine, MK-0867
Endocrine, MK-0974
Glaucoma, MK-0994
Infectious Disease, MK-0608
Infectious Disease, MK-7009
Infectious Disease, MK-8122
Infectious Disease (Flu), V512
Infectious Disease (S.aureus), V710
Insomnia, MK-0454
Insomnia, MK-8998
Osteoporosis, MK-0773
Parkinson’s Disease, MK-0657
Psychiatric Disease, MK-0249
Psychiatric Disease, MK-2637
Psychiatric Disease, MK-5757
Phase 2
Alzheimer’s Disease, MK-0249
Arthritis, MK-0822
Atherosclerosis, MK-0633
Atherosclerosis, MK-0859
Cancer, MK-0457
Cancer, MK-0822
Diabetes, MK-0533
Endocrine, MK-0677
HIV, V526
HPV, V502
Infectious Disease (Pediatric), V419
Migraine, MK-0974
Osteoporosis, MK-0822
Overactive Bladder, MK-0594
Overactive Bladder, MK-0634
Pain, MK-0759
Pain, MK-2295
Pain, MK-6721
Respiratory Disease, MK-0633
Stroke, MK-0724
Phase 3
Atherosclerosis, MK-0524A (ER niacin/laropiprant)
Atherosclerosis, MK-0524B
HIV, MK-0518 (raltegravir)
Insomnia, gaboxadol
Obesity, MK-0364 (taranabant)
Reviewing
CINV, Emend For Injection (MK-0517)
Diabetes, Janumet
Osteoarthritis, Arcoxia
Approvals
Cancer (CTCL), Zolinza
Cervical Cancer and Genital Warts, Gardasil
Diabetes, Januvia
Rotavirus Gastroenteritis, RotaTeq
Shingles, Zostavax
(1)Candidates shown in Phase 1 and 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Back–up compounds, regardless of their phase of development, additional indications in the same therapeutic areas, and additional claims, line extensions or formulations for in–line products are not shown.
(2)Candidates shown in Phase 3 include specific compounds.
